William Parker, MD
Allergy & Immunology · Beavercreek, OHNPI 1780665430
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Boehringer Ingelheim at 30.7% of the total.
Across 190 payments — averaging $58.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- AstraZeneca$2K
- Incyte Corporation$2K
- Sanofi$1K
- GSK$765
- Regeneron Healthcare Solutions, Inc.$629
- plus $1K from 18 others
What the payments were for
- Consulting fees$1,81716%
- Speaking & faculty fees$3,02027%
- Travel & lodging$1571%
- Food & beverage$5,93654%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $3,380 |
| AstraZeneca | 43 | $2,088 |
| Incyte Corporation | 2 | $1,752 |
| Sanofi | 49 | $1,139 |
| GSK | 19 | $765 |
| Regeneron Healthcare Solutions, Inc. | 19 | $629 |
| Optinose US, Inc. | 8 | $188 |
| Genentech USA, Inc. | 4 | $179 |
| Kaleo, Inc. | 10 | $151 |
| Novartis | 6 | $143 |
| Amgen | 1 | $122 |
| Aimmune Therapeutics, Inc. | 1 | $82 |
| Alk-abello, Inc | 3 | $52 |
| Pfizer | 3 | $51 |
| Blueprint Medicines Corporation | 2 | $50 |
| Stryker | 1 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Grifols USA, LLC | 2 | $39 |
| CSL Behring | 2 | $29 |
| Chiesi USA, Inc. | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,019 in reported general payments places this provider in the 70th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 28 | $118,611 |
| Dupixent PenDupilumab | 11 | $39,508 |
| Spiriva RespimatTiotropium Bromide | 52 | $27,936 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $15,268 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,950 |
| Epinephrine | 31 | $6,095 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $4,559 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,311 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $2,097 |
| Montelukast Sodium | 94 | $1,065 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,016 |
| Fluticasone Propionate | 53 | $863 |
| Azelastine Hcl | 43 | $681 |
| Hydroxyzine Hcl | 20 | $349 |
| Famotidine | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere | $2,088 | $133,87943 claims |
| Boehringer IngelheimSpiriva Respimat | $3,380 | $27,93652 claims |
| GSKBreo Ellipta, Anoro Ellipta | $765 | $17,50839 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $6,09531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Beavercreek
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
- David LangCleveland$251K
- James FernandezCleveland$179K
- Donald McNeilColumbus$136K
- Amber PattersonFindlay$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.